Double barrel approach
Posted: Mon Sep 10, 2012 4:07 am
So I understand that Tovaxin has been designed to work, by targeting T-Cells specifically involved in attacking Myelin. Now, on the other hand we have another treatment called Campath, which has shown some positive effectiveness by targeting CD52, a protein present on the surface of mature lymphocytes. I would think that the scientists would somehow also be able to train Tovaxin to also target CD52 as well as its current targets, and thereby combine the benefits of Tovaxin, with some of the benefits seen in Campath. Hopefully creating an even more effective treatment.
Thoughts?
Thoughts?